



## PRESS RELEASE

**For Immediate Release**

### ***Simple Test Could Affect How Millions Worldwide Receive Heart Disease Treatment***

*AspirinWorks® Test measures aspirin response in patients taking an aspirin a day*

*“Any individuals at increased risk for a heart attack ought to know if their aspirin dose is effective.” — Corgenix Clinical Affairs Director Gordon Ens*

**DENVER, Colo. — February 3, 2009** — An estimated 50 million Americans take an aspirin every day to prevent heart disease. But as many as one in four patients are resistant to the beneficial effects of aspirin. A simple test can give patients the answer for whether the treatment is working for them.

A study published in the American Heart Association’s journal, *Circulation*, recently confirmed that resistance to aspirin could lead to an increased risk of heart attack, stroke and cardiac death. In addition, a study from the *British Medical Journal* stated that heart patients who are resistant to aspirin are up to four times more likely to suffer a heart attack, stroke or die from cardiovascular disease. The research shows that people respond differently to the same dose of aspirin.

“We just sort of arrived at a figure that a baby aspirin a day would work. And, for some people we now know that is not true. They have aspirin resistance,” said Cardiologist Richard Collins, M.D., of South Denver Cardiology Associates. Each patient requires an individual dosage of aspirin according to their personalized treatment plan, he said.

Aspirin works by preventing the production of a molecule called thromboxane, a naturally produced chemical that causes platelets to stick together and clot. The AspirinWorks® Test by Corgenix Medical is the only FDA-cleared test that measures thromboxane levels in urine to determine the effect of aspirin in apparently healthy individuals.

Once patients are tested and shown not to respond to their aspirin therapy, doctors may modify their therapy by changing their aspirin dose or prescribing another antiplatelet medication.

“The advantage of the AspirinWorks Test is that it’s a urine sample, it’s very easy for the patient to collect and for a doctor to send to a laboratory to be tested,” said Corgenix Clinical Affairs Director Gordon Ens. “Any individuals at increased risk for a heart attack ought to know if their aspirin dose is effective.”

Chicago patient Tracey Powell followed a routine of taking an aspirin a day to ward off a heart attack. But what he and his doctor didn’t know was his level of resistance. “I took aspirin because my doctor told me to, and I just figured it worked,” Powell said.

The AspirinWorks Test allowed Powell to alter his treatment and take more control over his health. His doctor now performs the test annually to maintain a healthy aspirin dosage to protect his heart.

The AspirinWorks Test is available nationwide and covered by most insurance carriers and Medicare. Consumers can also obtain the test directly by visiting HealthCheckUSA’s Web site at [www.healthcheckusa.com](http://www.healthcheckusa.com). For more information on the AspirinWorks Test, visit [www.aspirinworks.com](http://www.aspirinworks.com).

### **About Corgenix Medical Corporation**

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for vascular diseases, immunology disorders, and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 52 diagnostic products through a global distribution network. More information is available at [www.corgenix.com](http://www.corgenix.com).

*Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.*

Company Contact:  
Corgenix Medical Corp.  
William Critchfield, Senior VP and CFO  
Phone: 303-453-8903  
Fax : 303-453-8898  
[wcritchfield@corgenix.com](mailto:wcritchfield@corgenix.com)

Media Contact:  
Armada Medical Marketing  
Dan Snyders  
Vice President, Public Relations Supervisor  
Phone: 303-623-1190 x 230  
[dan@armadamedical.com](mailto:dan@armadamedical.com)